CGRP

Calcitonin gene-related peptide (CGRP) is a 37-amino acid neuropeptide that exists in two forms: alpha-CGRP (predominantly in sensory neurons) and beta-CGRP (predominantly in enteric neurons). Alpha-CGRP is produced through tissue-specific alternative splicing of the calcitonin gene - the same gene that, when spliced differently in thyroid C-cells, produces calcitonin for calcium regulation. This unusual biology - two completely different peptides from the same gene depending on splicing patterns in different tissues - was a landmark discovery in molecular biology.

CGRP is the most potent endogenous vasodilator known in the peripheral circulation, with EC50 values in the picomolar range in human forearm blood flow studies. This vasodilatory potency reflects the widespread distribution of CGRP receptors on vascular smooth muscle and endothelium throughout the body. The CGRP receptor is a complex heterodimer of the calcitonin receptor-like receptor (CLR) and receptor activity-modifying protein 1 (RAMP1) - a molecular architecture that has attracted considerable pharmacological interest since the receptor can be specifically targeted without affecting calcitonin or related peptide signalling.

The pivotal insight that transformed CGRP from an interesting vasoactive peptide into the primary target of migraine pharmacology came from several converging lines of evidence in the late 1980s and 1990s. Lance and Goadsby demonstrated that CGRP is released into jugular venous blood during migraine attacks. Edvinsson's group showed that CGRP is the predominant sensory neuropeptide in trigeminal neurons innervating the dural vasculature - the anatomical substrate for headache pain. IV infusion of CGRP reliably triggered migraine attacks in migraineurs. The hypothesis that CGRP released from activated trigeminal neurons drives dural vasodilation, neurogenic inflammation, and central sensitisation during migraine became the dominant mechanistic framework.

The therapeutic validation of this hypothesis followed decades of drug development. The "gepant" class of small-molecule CGRP receptor antagonists (olcegepant, telcagepant, rimegepant, ubrogepant, zavegepant) demonstrated proof-of-concept for CGRP receptor blockade as acute migraine treatment - matching or exceeding triptans in some studies without triptan-associated vasoconstriction. The anti-CGRP monoclonal antibodies (erenumab targeting the CGRP receptor; fremanezumab and galcanezumab targeting the ligand itself; eptinezumab administered IV) represented the first treatments specifically designed and validated against the migraine mechanism. All four are now FDA-approved for migraine prevention and have shown 50% responder rates of 40-70% in clinical trials.

Beyond migraine, CGRP has important roles in cardiovascular physiology. The heart contains abundant CGRP-positive sensory nerve fibres, and CGRP released locally during myocardial ischemia acts as an endogenous cardioprotective mechanism - dilating coronary microvasculature, reducing heart rate, and limiting infarct size in preclinical models. Epidemiological concern arose that anti-CGRP therapies might reduce this cardioprotection in patients with concurrent cardiovascular disease, though clinical data to date have not revealed increased cardiovascular events in approved trials.

The bone biology of CGRP reveals yet another dimension of this peptide's physiological importance. CGRP-immunoreactive nerve fibres are abundant in periosteum and bone marrow. CGRP receptors on osteoblasts stimulate bone formation, while CGRP inhibits osteoclastic bone resorption. Mice lacking alpha-CGRP show reduced bone density and impaired fracture healing, suggesting a regulatory role in skeletal homeostasis. The potential long-term effects of anti-CGRP therapies on bone metabolism represent an ongoing area of post-marketing surveillance.